GlassScriptPhysician profile
Marre P Henry
NPI 1891719076
$4,840.17
in general payments reported to CMS, 2019-2025
30 companies · $1,676 in 2025
The $1,676 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $717 · 2022: $404 · 2023: $673 · 2024: $1,371 · 2025: $1,676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,720.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,719.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,366.93 | 2021-2025 | |
| Janssen Biotech, INC. | $531.77 | 2021-2025 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $424.04 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Regeneron Healthcare Solutions, INC. | $402.78 | 2023-2025 | Dupixent |
| Lilly USA, LLC | $368.10 | 2023-2025 | Omvoh, Zepbound |
| Madrigal Pharmaceuticals | $319.30 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $265.33 | 2023-2025 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $205.81 | 2021-2025 | Entyvio, Gattex |
| Merck Sharp & Dohme LLC | $147.79 | 2021-2024 | Dificid |
| Pfizer INC. | $98.14 | 2023-2025 | |
| Genzyme Corporation | $95.76 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $94.36 | 2024-2025 | Voquezna |
| Daiichi Sankyo INC. | $65.26 | 2021-2022 | |
| Qol Medical, LLC | $51.30 | 2024-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $49.83 | 2021-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $37.65 | 2022-2023 | Ibsrela |
| Celgene Corporation | $37.44 | 2024 | Zeposia |
| Organon LLC | $32.53 | 2024-2025 | Hadlima, Renflexis |
| Amgen INC. | $32.07 | 2023 | Avsola, Amjevita |
| Redhill Biopharma INC. | $28.35 | 2021-2024 | Talicia |
| Braintree Laboratories, INC. | $22.59 | 2024 | Suflave, Sutab |
| Ipsen Biopharmaceuticals, INC | $21.74 | 2024 | Iqirvo |
| Aimmune Therapeutics, INC. | $20.79 | 2025 | Zenpep |
| Vivus LLC | $20.65 | 2025 | Pancreaze |
| Celltrion USA INC. | $20.10 | 2024 | Vegzelma |
| Novo Nordisk INC | $19.24 | 2025 | Wegovy |
| Fresenius Kabi USA, LLC | $16.05 | 2023 | Idacio |
| Nestle Healthcare Nutrition INC. | $15.64 | 2022 | |
| Ferring Pharmaceuticals INC. | $15.35 | 2023 | Rebyota |
| Evoke Pharma, INC. | $13.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marre Henry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.